Altis Biosystems
About Altis Biosystems
Altis Biosystems develops RepliGut® Systems, a collection of in vitro models derived from human stem cells that accurately replicate the human intestinal environment for pre-clinical drug discovery. These models enable pharmaceutical companies to assess drug absorption, toxicity, and efficacy earlier in the development process, reducing reliance on animal testing and enhancing the safety and efficiency of clinical trials.
```xml <problem> Current preclinical drug discovery methods for human intestinal disorders lack user-friendly pharmacological testing models, hindering the development of new therapies and the safe passage of orally administered treatments through the gut. Traditional cell lines and animal models often fail to accurately represent human intestinal physiology, leading to poor clinical translation. </problem> <solution> Altis Biosystems develops RepliGut® Systems, a suite of in vitro models derived from human stem cells that replicate the structure and function of the human small intestine and colonic epithelium. These models provide a reproducible and scalable platform for studying drug disposition and pharmacology, including toxicity, metabolism, drug absorption, and efficacy. RepliGut® models offer valuable data insights, rapid screening capabilities, and a biobank of ethically sourced donor intestinal cells, facilitating more effective compound screening, disease modeling, and microbiome research, while reducing the need for animal testing. </solution> <features> - RepliGut® Planar: A membrane-supported culture platform recreating the biology of the human intestine, enabling study of inflammation, toxicity, bioavailability, and host-microbe interactions. - RepliGut® Crypt: Mimics the cellular lifecycle of the intestinal crypt, allowing for compound screening, disease modeling, drug disposition analysis, and efficacy studies. - Standardized plate format with apical and basal surface access for a wide range of assays. - Biomimetic scaffold supporting cell well-being and providing a protective barrier. - Apical and basal reservoirs enabling interaction of compounds, cell types, and epithelial cells on both surfaces. - Available as RepliGut® Kits, complete with cells, plates, and media for in-house culturing. - Custom services are available for specialized projects. - Multiple donor biobank with regional specificity from the small intestine and colon. </features> <target_audience> The primary customers are pharmaceutical companies and life science researchers involved in preclinical drug discovery and development, seeking to improve the safety and efficacy of orally administered therapeutics and develop new treatments for intestinal disorders. </target_audience> ```
What does Altis Biosystems do?
Altis Biosystems develops RepliGut® Systems, a collection of in vitro models derived from human stem cells that accurately replicate the human intestinal environment for pre-clinical drug discovery. These models enable pharmaceutical companies to assess drug absorption, toxicity, and efficacy earlier in the development process, reducing reliance on animal testing and enhancing the safety and efficiency of clinical trials.
Where is Altis Biosystems located?
Altis Biosystems is based in Durham, United States.
When was Altis Biosystems founded?
Altis Biosystems was founded in 2015.
How much funding has Altis Biosystems raised?
Altis Biosystems has raised 6650000.
- Location
- Durham, United States
- Founded
- 2015
- Funding
- 6650000
- Employees
- 27 employees